Drug intelligence / Profile preview

diosmin

Development stage
Phase 4
Lead developer
Servier
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Diosmin is a naturally occurring flavonoid glycoside found mainly in citrus fruits and used as a venoactive drug to support vascular health. It is primarily indicated for the treatment of chronic venous insufficiency (CVI), hemorrhoids, varicose veins, and venous leg ulcers. Diosmin acts as a phlebotonic and vascular protector by improving lymphatic drainage, increasing venous tone and capillary resistance, reducing capillary permeability, and enhancing microcirculation. Its mechanism of action includes inhibition of noradrenaline metabolism in the venous wall—prolonging smooth muscle contraction—and modulation of lymphatic vessel function. Diosmin also exhibits antioxidant, anti-inflammatory, antidiabetic, antihyperlipidemic, antifibrotic, antibacterial properties in various disease models[2][3][5][6]. It is available over-the-counter in many countries (often as micronized purified flavonoid fraction or MPFF) with a favorable safety profile[4].

Brand names
DaflonDetralex
Other names
micronized purified flavonoid fractionMPFF
02

Targets

AHR (Aryl hydrocarbon receptor)CYP1A1 (Cytochrome P450 1A1)

Beyond the preview

Go deeper on diosmin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diosmin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call